Article

Lower Mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

2020-11-03

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Bladder cancer displays a broad mutational spectrum and intratumor heterogeneity (ITH), which results in difference in molecular phenotypes and resistance to therapies. However, there are currently no clinically available measures to predict patient prognosis using ITH. We aimed to establish clinically relevant biomarker by using ITH for informing predictive of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5f7a732e-23e6-57bf-8e30-944004926735
DOI: 10.21203/rs.3.rs-62350/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lower Mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosisDOI 10.21203/rs.3.rs-62350/v2Read

Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.Semantic proximity Read

Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer.Semantic proximity Read

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomesSemantic proximity Read

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.Semantic proximity Read

Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer.Semantic proximity Read

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Semantic proximity Read

Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing.Semantic proximity Read

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.Semantic proximity Read

Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung AdenocarcinomaSemantic proximity Read

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.Semantic proximity Read

Tumor heterogeneity in muscle-invasive bladder cancerSemantic proximity Read

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read